Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients

N/AUnknownNCT05679648

Sohag University100 enrolled

Overview

studying the prevalence of hepatic steatosis and fibrosis in a large scale of patients with RA and healthy controls

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Hepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients

Interventions

ultrasonographyDIAGNOSTIC_TEST

studying degree of steatosis

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. RA according to the American College of Rheumatology (ACR)/EULAR 2010 criteria (Aletaha et al., 2010) 2. Age≥18 years Exclusion Criteria: * History of hepatitis B and C virus infection. * Receiving hepatotoxic drugs other than RA-specific drugs. * Alcohol abuse (i30 g/day in men and ⩾20 g/day in women). * Diagnosis of Wilson's disease, α1-antitrypsin deficiency or hemochromatosis. * Autoimmune liver disease. * Cancer. * Pregnancy.

Outcomes

Primary Outcomes

degree of hepatic steatosis

degree of hepatic steatosis by ultrasonography and Hepatic Steatosis Index.

Time frame: 1 day during examination

degree of hepatic fibrosis

degree of hepatic fibrosis by FIB-4 and APRI tests

Time frame: 1 day during examination

Central Contacts

Amr Ahmed, Lecturer

CONTACT

02/01007065530 amr.hamed@med.sohag.edu.eg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.